Biomea Fusion, Inc. Common Stock
BMEAStock
$1.26−33.51%52W
Market Cap$93.27M
P/E—
Div yield—
Beta-0.33
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-6.29%
Price vs S&P 500 (4W)7.90%
VGM Score36.14
Market Capitalization$93.27M
Earnings Surprise History
Q1 26-0.17est. -0.24
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.15
4.15
4.15
4.15
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BMEABiomea Fusion, Inc. Common Stock | — | — | D | $1.26 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Biomea Fusion is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for diabetes and obesity. Its lead candidate, icovamenib, is a covalent menin inhibitor in clinical trials for type 1 and type 2 diabetes and obesity, while BMF-650, an oral GLP-1 receptor agonist, is in development for the same indications. The company leverages its proprietary FUSION System platform to discover novel drug candidates targeting metabolic diseases.